Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis.
Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Bozkaya H, Schlaphoff V, Dienes HP, Bock TC, Manns MP, Wedemeyer H; HIDT-1 Study Group. Zachou K, et al. Among authors: erhardt a. Liver Int. 2010 Mar;30(3):430-7. doi: 10.1111/j.1478-3231.2009.02140.x. Epub 2009 Oct 16. Liver Int. 2010. PMID: 19840253
Peginterferon plus adefovir versus either drug alone for hepatitis delta.
Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group. Wedemeyer H, et al. Among authors: erhardt a. N Engl J Med. 2011 Jan 27;364(4):322-31. doi: 10.1056/NEJMoa0912696. N Engl J Med. 2011. PMID: 21268724 Free article. Clinical Trial.
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment.
Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. Mederacke I, et al. Among authors: erhardt a. Antivir Ther. 2012;17(2):305-12. doi: 10.3851/IMP1926. Epub 2011 Oct 24. Antivir Ther. 2012. PMID: 22293066
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis.
Kabaçam G, Dalekos GN, Çakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçin K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Kabaçam G, et al. Among authors: erhardt a. Turk J Gastroenterol. 2012;23(5):560-8. doi: 10.4318/tjg.2012.0538. Turk J Gastroenterol. 2012. PMID: 23161302 Free article. Clinical Trial.
Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta.
Kabaçam G, Wedemeyer H, Savaş B, Keskin O, Dalekos G, Tabak F, Idilman R, Erhardt A, Yalçın K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydın C; HIDIT-1 Study Group. Kabaçam G, et al. Among authors: erhardt a. Liver Int. 2014 Sep;34(8):1207-15. doi: 10.1111/liv.12376. Epub 2013 Dec 5. Liver Int. 2014. PMID: 24308704 Clinical Trial.
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Heidrich B, et al. Among authors: erhardt a. Hepatology. 2014 Jul;60(1):87-97. doi: 10.1002/hep.27102. Hepatology. 2014. PMID: 24585488
Anti-HDV IgM as a marker of disease activity in hepatitis delta.
Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group. Wranke A, et al. Among authors: erhardt a. PLoS One. 2014 Jul 29;9(7):e101002. doi: 10.1371/journal.pone.0101002. eCollection 2014. PLoS One. 2014. PMID: 25072849 Free PMC article.
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
Anastasiou OE, Yurdaydin C, Maasoumy B, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Liebig S, Bantel H, Bremer B, Manns MP, Cornberg M, Wedemeyer H. Anastasiou OE, et al. Among authors: erhardt a. J Viral Hepat. 2021 Feb;28(2):410-419. doi: 10.1111/jvh.13439. Epub 2020 Dec 12. J Viral Hepat. 2021. PMID: 33185325 Clinical Trial.
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Bremer B, Anastasiou OE, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Idilman R, Manns MP, Cornberg M, Yurdaydin C, Wedemeyer H. Bremer B, et al. Among authors: erhardt a. Liver Int. 2021 Feb;41(2):295-299. doi: 10.1111/liv.14740. Epub 2020 Dec 5. Liver Int. 2021. PMID: 33217778
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team. Wedemeyer H, et al. Among authors: erhardt a. Lancet Infect Dis. 2019 Mar;19(3):275-286. doi: 10.1016/S1473-3099(18)30663-7. Lancet Infect Dis. 2019. PMID: 30833068 Clinical Trial.
253 results